Facebook (FB) Shareholder Boys Arnold & Co Has Increased Holding by $6.64 Million; As Abbvie Com (ABBV) Stock Value Declined, Holder Butensky & Cohen Financial Security Has Trimmed Its Position

Facebook, Inc. (NASDAQ:FB) Logo

Butensky & Cohen Financial Security Inc decreased its stake in Abbvie Inc Com (ABBV) by 26.16% based on its latest 2018Q1 regulatory filing with the SEC. Butensky & Cohen Financial Security Inc sold 6,185 shares as the company’s stock declined 16.83% with the market. The institutional investor held 17,455 shares of the major pharmaceuticals company at the end of 2018Q1, valued at $1.65M, down from 23,640 at the end of the previous reported quarter. Butensky & Cohen Financial Security Inc who had been investing in Abbvie Inc Com for a number of months, seems to be less bullish one the $139.95B market cap company. The stock increased 1.01% or $0.92 during the last trading session, reaching $92.43. About 6.70 million shares traded. AbbVie Inc. (NYSE:ABBV) has risen 52.41% since June 29, 2017 and is uptrending. It has outperformed by 39.84% the S&P500. Some Historical ABBV News: 07/03/2018 – Biogen, AbbVie’s Zinbryta, Yanked From Market, Connected To Three U.S. Cases Of Brain Inflammation — MarketWatch; 10/04/2018 – BerGenBio Completes Recruitment Into First Stage of Phase Il NSCLC Trial With Selective AXL Inhibitor Bemcentinib Combined With KEYTRUDA®; 01/05/2018 – AbbVie Commences Self-Tender Offer for Up to $7.5B of Its Common Stk; 10/04/2018 – ABBVIE INC – BASED ON ABBVIE’S REVIEW OF DATA, COMPANY REMAINS CONFIDENT IN NDA AND CONTINUES TO WORK WITH FDA TO BRING ELAGOLIX TO PATIENTS; 17/04/2018 – REG-Genmab Announces Net Sales of DARZALEX® (daratumumab) for First Quarter of 2018; 20/03/2018 – EXACT SCIENCES CORP – STENHOUSE, VICE PRESIDENT, U.S. IMMUNOLOGY AT ABBVIE, WILL ASSUME NEW POSITION ON APRIL 2, 2018; 25/05/2018 – Oncolytics Biotech Collaborates With USC Using Pelareorep in Combination With Keytruda, Velcade and Dexamethasone to Treat Multiple Myeloma; 10/04/2018 – AbbVie: Elagolix Clinical Trial Program Largest Prospective Randomized Endometriosis Trial Conducted to Date; 17/04/2018 – Dynavax Provides New Durability of Response Data for SD-101 in Combination with KEYTRUDA® (pembrolizumab) in Melanoma at the 2; 30/05/2018 – GILEAD SCIENCES INC – EPCLUSA IS FIRST PAN-GENOTYPIC HCV SINGLE TABLET REGIMEN (STR) APPROVED IN CHINA

Boys Arnold & Co Inc increased its stake in Facebook Inc (FB) by 583.56% based on its latest 2018Q1 regulatory filing with the SEC. Boys Arnold & Co Inc bought 39,997 shares as the company’s stock declined 0.01% with the market. The institutional investor held 46,851 shares of the technology company at the end of 2018Q1, valued at $7.79 million, up from 6,854 at the end of the previous reported quarter. Boys Arnold & Co Inc who had been investing in Facebook Inc for a number of months, seems to be bullish on the $568.01B market cap company. The stock increased 0.20% or $0.39 during the last trading session, reaching $196.23. About 17.23 million shares traded. Facebook, Inc. (NASDAQ:FB) has risen 21.69% since June 29, 2017 and is uptrending. It has outperformed by 9.12% the S&P500. Some Historical FB News: 27/03/2018 – CAMBRIDGE ANALYTICA SAYS A FURTHER INDEPENDENT AUDIT ALONGSIDE REGULATORY INVESTIGATIONS WILL “CONFIRM THIS ONCE AND FOR ALL” – TWEET; 04/04/2018 – Facebook announced on Wednesday afternoon that it would tighten restrictions on third-party access to user data; 19/03/2018 – Here’s how Facebook ad tracking and targeting works; 08/05/2018 – David Cochrane: EXCLUSIVE by @ciaraobrien: Facebook announces ban on foreign-funded advertisements aimed at #8thre; 27/03/2018 – Facebook’s Reed on Data Privacy, MLB Partnership (Video); 05/03/2018 – New York Post: Facebook survey asks users if they condone pedophilia; 03/04/2018 – Facebook is removing more than 270 pages and accounts operated by Russian organization Internet Research Agency (IRA) intended to influence Russian users; 30/05/2018 – Fox CEO James Murdoch rips Facebook as an ‘attack surface’; 14/05/2018 – ♫ Reuters Insider – Facebook suspends 200 apps; 25/04/2018 – MACRON SAYS IRAN POLICY SHOULD NEVER LEAD US TO WAR IN THE MIDDLE EAST

Among 24 analysts covering Abbvie Inc (NYSE:ABBV), 9 have Buy rating, 3 Sell and 12 Hold. Therefore 38% are positive. Abbvie Inc had 97 analyst reports since July 21, 2015 according to SRatingsIntel. On Monday, January 29 the stock rating was maintained by Credit Suisse with “Hold”. The stock of AbbVie Inc. (NYSE:ABBV) has “Neutral” rating given on Friday, June 1 by PiperJaffray. The firm has “Buy” rating given on Friday, February 2 by Argus Research. The stock of AbbVie Inc. (NYSE:ABBV) has “Buy” rating given on Wednesday, July 22 by SunTrust. Morgan Stanley maintained the stock with “Equal-Weight” rating in Monday, April 30 report. On Friday, February 5 the stock rating was initiated by William Blair with “Outperform”. BMO Capital Markets maintained AbbVie Inc. (NYSE:ABBV) rating on Wednesday, May 23. BMO Capital Markets has “Underperform” rating and $78 target. Atlantic Securities initiated the shares of ABBV in report on Friday, December 18 with “Neutral” rating. As per Monday, January 29, the company rating was downgraded by Leerink Swann. The rating was downgraded by Goldman Sachs on Monday, March 7 to “Buy”.

Since February 19, 2018, it had 1 insider buy, and 10 insider sales for $26.70 million activity. Shares for $2.95M were sold by Schumacher Laura J. The insider Michael Robert A. sold 4,294 shares worth $512,853. Another trade for 83,574 shares valued at $9.57 million was sold by ALBAN CARLOS. $157,458 worth of AbbVie Inc. (NYSE:ABBV) was sold by SALEKI-GERHARDT AZITA on Wednesday, February 28. Another trade for 2,643 shares valued at $311,684 was made by SEVERINO MICHAEL on Wednesday, February 28. The insider RAPP EDWARD J bought 1,013 shares worth $99,909.

Investors sentiment decreased to 0.7 in Q1 2018. Its down 0.10, from 0.8 in 2017Q4. It worsened, as 61 investors sold ABBV shares while 737 reduced holdings. 127 funds opened positions while 428 raised stakes. 1.06 billion shares or 0.67% less from 1.06 billion shares in 2017Q4 were reported. Iowa State Bank invested 2.74% of its portfolio in AbbVie Inc. (NYSE:ABBV). Field & Main Comml Bank reported 1.02% of its portfolio in AbbVie Inc. (NYSE:ABBV). Cannell Peter B & Com holds 1.79% of its portfolio in AbbVie Inc. (NYSE:ABBV) for 502,728 shares. Coe Mngmt Limited Liability Corp invested in 2.67% or 25,982 shares. Markston International Ltd holds 1.27% or 124,331 shares in its portfolio. British Columbia Inv Mngmt Corporation reported 0.49% in AbbVie Inc. (NYSE:ABBV). South Dakota Council accumulated 41,600 shares. Interocean Cap Limited Com has 6,717 shares. Norris Perne French Ltd Liability Partnership Mi has invested 0.41% in AbbVie Inc. (NYSE:ABBV). M Kraus And has 3.99% invested in AbbVie Inc. (NYSE:ABBV) for 66,428 shares. Prudential Public Ltd Liability holds 0.72% or 2.42M shares. Accredited Invsts has 0.09% invested in AbbVie Inc. (NYSE:ABBV) for 3,598 shares. Mutual Of Omaha State Bank Wealth Mgmt reported 3.31% stake. Intl invested in 5.54 million shares or 1.83% of the stock. Baker Avenue Asset Management Lp holds 33,817 shares or 0.29% of its portfolio.

More notable recent AbbVie Inc. (NYSE:ABBV) news were published by: Seekingalpha.com which released: “More Thoughts On AbbVie’s Rova-T Implosion” on June 06, 2018, also Seekingalpha.com with their article: “AbbVie: Growth And Dividend In One Package” published on June 15, 2018, Streetinsider.com published: “argenx (ARGX) Secures Second Pre-Clinical Milestone Payment of $10M from AbbVie (ABBV) for ARGX-115 …” on June 28, 2018. More interesting news about AbbVie Inc. (NYSE:ABBV) were released by: Seekingalpha.com and their article: “AbbVie On A Roll, Buy AbbVie” published on June 28, 2018 as well as Investorideas.com‘s news article titled: “AbbVie (NYSE: ABBV) and Calibr announce collaboration for next generation T-cell therapies” with publication date: June 25, 2018.

Analysts await AbbVie Inc. (NYSE:ABBV) to report earnings on July, 27. They expect $1.97 earnings per share, up 38.73% or $0.55 from last year’s $1.42 per share. ABBV’s profit will be $2.98 billion for 11.73 P/E if the $1.97 EPS becomes a reality. After $1.87 actual earnings per share reported by AbbVie Inc. for the previous quarter, Wall Street now forecasts 5.35% EPS growth.

Among 55 analysts covering Facebook (NASDAQ:FB), 50 have Buy rating, 2 Sell and 3 Hold. Therefore 91% are positive. Facebook had 275 analyst reports since July 21, 2015 according to SRatingsIntel. The rating was maintained by RBC Capital Markets with “Buy” on Wednesday, September 6. On Thursday, April 28 the stock rating was maintained by Goldman Sachs with “Buy”. The stock of Facebook, Inc. (NASDAQ:FB) has “Buy” rating given on Thursday, November 2 by J.P. Morgan. Citigroup maintained it with “Buy” rating and $133 target in Friday, April 1 report. The rating was initiated by Loop Capital with “Buy” on Friday, September 23. Cowen & Co maintained the shares of FB in report on Thursday, April 28 with “Outperform” rating. The stock of Facebook, Inc. (NASDAQ:FB) has “Buy” rating given on Tuesday, July 28 by Axiom Capital. The stock of Facebook, Inc. (NASDAQ:FB) earned “Buy” rating by Canaccord Genuity on Thursday, November 3. The stock has “Positive” rating by Susquehanna on Thursday, April 28. On Tuesday, January 3 the stock rating was initiated by Aegis Capital with “Buy”.

Investors sentiment decreased to 0.87 in 2018 Q1. Its down 0.34, from 1.21 in 2017Q4. It turned negative, as 145 investors sold FB shares while 712 reduced holdings. 173 funds opened positions while 573 raised stakes. 1.65 billion shares or 2.41% more from 1.61 billion shares in 2017Q4 were reported. Cantillon Mngmt Ltd Liability Company reported 1.32% stake. Cadinha And Co Ltd Liability holds 0.11% of its portfolio in Facebook, Inc. (NASDAQ:FB) for 3,385 shares. The Ontario – Canada-based 1832 Asset Management Ltd Partnership has invested 0.05% in Facebook, Inc. (NASDAQ:FB). Provident Mgmt reported 1,383 shares. Wcm Inv Ca has 0.65% invested in Facebook, Inc. (NASDAQ:FB). Glenmede Na accumulated 918,486 shares or 0.68% of the stock. Moody National Bank & Trust Division stated it has 0.12% of its portfolio in Facebook, Inc. (NASDAQ:FB). Holderness Invests holds 0.72% or 9,090 shares in its portfolio. Mirador Cap Prtn Limited Partnership holds 2.88% in Facebook, Inc. (NASDAQ:FB) or 23,994 shares. Peak Asset Lc holds 0.21% or 3,653 shares. Financial Advisory stated it has 2,563 shares. Moreover, 10 has 0.07% invested in Facebook, Inc. (NASDAQ:FB) for 1,898 shares. Lombard Odier Asset Mngmt (Europe) has invested 0.25% in Facebook, Inc. (NASDAQ:FB). Coatue Limited Liability Company invested in 5.70M shares or 7.52% of the stock. Badgley Phelps Bell has 110,211 shares for 1.17% of their portfolio.

Boys Arnold & Co Inc, which manages about $1.02B and $686.22 million US Long portfolio, decreased its stake in Apple Inc (Put) (NASDAQ:AAPL) by 47,615 shares to 53,000 shares, valued at $8.81M in 2018Q1, according to the filing. It also reduced its holding in Enterprise Prods Partners L (NYSE:EPD) by 12,232 shares in the quarter, leaving it with 15,412 shares, and cut its stake in Aetna Inc New (NYSE:AET).

Facebook, Inc. (NASDAQ:FB) Institutional Positions Chart